Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
Demonstrate significant bleed reduction in hemophilia A and B
Express Scripts to add Zepbound to National Preferred Formulary
NATCO temporarily shut down the operations due to cyclone with flooding/water logging of the factory premises
Subscribe To Our Newsletter & Stay Updated
